Refractory/relapse thrombocytopenia in a patient with Evans' syndrome successfully treated with zanubrutinib

Br J Haematol. 2022 Dec;199(5):e37-e42. doi: 10.1111/bjh.18490. Epub 2022 Oct 12.

Authors

Menguan Li^{1

2}, Liu Liu³, Bingjie Ding^{1

2}, Xuewen Song^{1

2}, Ao Xia^{1

2}, Yu Han⁴, Yongping Song³, Xudong Wei¹, Hu Zhou^{1

2}

Affiliations

¹ Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
² Hemostasis and Thrombosis Diagnostic Engineering Research Center of Henan Province, Zhengzhou, China.
³ Department of Hematology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
⁴ Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, China.

PMID: 36223900
DOI: 10.1111/bjh.18490

No abstract available

Keywords: Bruton's tyrosine kinase inhibitor; Evans' syndrome; autoimmune haemolytic anaemia; immune thrombocytopenia; zanubrutinib.

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anemia, Hemolytic, Autoimmune*
Humans
Recurrence
Thrombocytopenia* / drug therapy

Substances

zanubrutinib

Supplementary concepts

Evans Syndrome

Associated data

ChiCTR/ChiCTR220060868